Buscar.
Resultados de la búsqueda 10
AmoyDx® Essential NGS panel got approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
Noticias & eventos
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA（National Medical Products Administration）approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
Noticias & eventos
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017
· Merck is the first pharmaceutical company to collaborate with multiple
Noticias & eventos
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine
Noticias & eventos
NRAS Mutation Detection Kit
PRODUCTOS
KRAS/NRAS Mutations Detection Kit
PRODUCTOS
KRAS/NRAS/BRAF Mutations Detection Kit
PRODUCTOS
Essential NGS Panel
A precise NGS panel, focusing on 10 genes which have clear evidence to the targeted therapy.
PRODUCTOS
BRAF-L2-02 BRAFV600E and NRASQ61L_Q61R mutation analysis in metastatic melanoma using immunohistochemistry_ a study of 754 cases
Descargar
KNBP-L1-01 Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients_ analysis of 1,110
Descargar
no más...
AmoyDx® Essential NGS panel got approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
Noticias & eventos
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA（National Medical Products Administration）approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
Noticias & eventos
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017
· Merck is the first pharmaceutical company to collaborate with multiple
Noticias & eventos
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine
Noticias & eventos
no más...